Zevra Therapeutics (ZVRA) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to -$0.01.
- Zevra Therapeutics' EPS (Weighted Average and Diluted) rose 9855.07% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.03, marking a year-over-year increase of 10254.24%. This contributed to the annual value of -$2.11 for FY2021, which is 3426.79% up from last year.
- Per Zevra Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.01 for Q3 2025, which was up 9855.07% from $1.21 recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' EPS (Weighted Average and Diluted) registered a high of $1.21 during Q2 2025, and its lowest value of -$2.49 during Q1 2021.
- Over the past 3 years, Zevra Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.23 (recorded in 2021), while the average stood at -$0.36.
- Per our database at Business Quant, Zevra Therapeutics' EPS (Weighted Average and Diluted) plummeted by 29047.62% in 2021 and then soared by 35208.33% in 2025.
- Zevra Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.05 in 2021, then tumbled by 1480.0% to -$0.69 in 2024, then surged by 98.55% to -$0.01 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.01 in Q3 2025, compared to $1.21 in Q2 2025 and -$0.69 in Q3 2024.